Search
Joint EHA and national society membership
Enjoy the best of both worlds—and save money—by combining an EHA membership with membership of your national hematology society. This special type of membership package is the result of our constructive collaborations with a range of national hematology societies.
Read moreEHA-EBMT 3rd European CAR T-cell Meeting (Virtual)
Dates: February 4-6, 2021
Chairs: H Einsele (EHA) & C Chabannon (EBMT)
For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…
Effective treatment of aging patients with hematological diseases discussed during SWG Aging meeting in Poland
The progress in the field of aging and the optimal and rational approaches of "fit" and "unfit" older patients with malignant hemopathies was the focus of the three-day EHA-SWG Scientific Meeting on Aging and Hematology held on October 12-14, 2018 in…
Read moreHighlights of Past EHA (HOPE) Asia 2020
October 16-17 2020
Meeting Chairs:
Dr N Senadheera (Sri Lanka College of Haematologists)
Prof J Gribben (European Hematology Association)
This second edition of HOPE Asia was presented together with the Sri Lanka College of Haematologists (SLCH) on October 16 and 17, 2020.…
EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias
Dates: September 21-22, 2018
Location: Warsaw, Poland
Chairs: T Robak, G Gaidano, I Hus
Following successful previous editions, EHA is coordinating the third two-day tutorial in close collaboration with the Polish Society of Hematology and Transfusion Medicine on “Myeloid and Lymphoid Leukemias”.…
Help disseminate IVDR Questionnaire - Share with diagnostic laboratories in your network
The new EU Regulation on in vitro diagnostic medical devices (IVDR) will come into full effect per May 26, 2022 and will have substantial consequences for diagnostic laboratories.
Read moreDoes the patient with myelofibrosis feel better through Pacritinib?
Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- »